{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009814","form_type":"8-K","ticker":"ATRC","cik":"0001323885","company_name":"AtriCure, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.791317+00:00","generated_at":"2026-05-16T10:47:52.725566+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M","bullets":["Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).","FY 2025 revenue $534.5M (+15% YoY); adj. EBITDA $57-59M; adj. loss per share $0.18-0.21.","Ended 2025 with $167M cash; expects positive cash flow and net income in 2026.","2026 revenue guidance $600-610M (+12-14%); adj. EBITDA $80-82M.","Amended credit facility extended 3 years, reduced interest rate, removed minimum utilization covenant."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009814","json":"https://secwatch.observer/filing/0001193125-26-009814.json","markdown":"https://secwatch.observer/filing/0001193125-26-009814.md","text":"https://secwatch.observer/filing/0001193125-26-009814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1323885/000119312526009814/0001193125-26-009814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1323885/000119312526009814/d43112d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:47:52.725566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df50c4c16051d4f0ceba6b8119960b1bd939c1a1","claim":"AtriCure, Inc. amended First Amendment to Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto (effective 2026-01-09).","evidence_excerpt":"On January 9, 2026 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into a First Amendment (“ First Amendment ”) to Credit Agreement (as amended, the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A., as bookrunner and lead arranger (“ JPMCB ”), and the lenders party thereto (“ Lenders ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1323885/000119312526009814/0001193125-26-009814-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A., as administrative agent, bookrunner and lead arranger, and the lenders party thereto"},{"label":"Effective","value":"2026-01-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}